Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
J Clin Oncol
; 39(26): 2959-2961, 2021 09 10.
Article
em En
| MEDLINE
| ID: mdl-34343058
ABSTRACT
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Biomarcadores Tumorais
/
Mutação em Linhagem Germinativa
/
Receptor ErbB-2
/
Proteína BRCA1
/
Inibidores de Poli(ADP-Ribose) Polimerases
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article